393 related articles for article (PubMed ID: 25572273)
21. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.
Raebel MA; Ross C; Xu S; Roblin DW; Cheetham C; Blanchette CM; Saylor G; Smith DH
J Gen Intern Med; 2010 Apr; 25(4):326-33. PubMed ID: 20087674
[TBL] [Abstract][Full Text] [Related]
22. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
23. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
24. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
25. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
Bakris G; Yang YF; Pitt B
Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
[TBL] [Abstract][Full Text] [Related]
26. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
27. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
28. Beneficial impact of spironolactone in diabetic nephropathy.
Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
[TBL] [Abstract][Full Text] [Related]
29. Comparison of agents that affect aldosterone action.
Tamargo J; Solini A; Ruilope LM
Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
[TBL] [Abstract][Full Text] [Related]
30. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
31. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
Chang AR; Sang Y; Leddy J; Yahya T; Kirchner HL; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
Hypertension; 2016 Jun; 67(6):1181-8. PubMed ID: 27067721
[TBL] [Abstract][Full Text] [Related]
33. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
34. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
[TBL] [Abstract][Full Text] [Related]
35. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Buysse JM; Huang IZ; Pitt B
Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
[TBL] [Abstract][Full Text] [Related]
36. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
Kauffmann R; Orozco R; Venegas JC
Rev Med Chil; 2005 Aug; 133(8):947-52. PubMed ID: 16163434
[TBL] [Abstract][Full Text] [Related]
37. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
Hou J; Xiong W; Cao L; Wen X; Li A
Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
[TBL] [Abstract][Full Text] [Related]
38. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
39. Aldosterone blockade in chronic kidney disease.
Hirsch JS; Drexler Y; Bomback AS
Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
[TBL] [Abstract][Full Text] [Related]
40. Hyperkalaemia in the age of aldosterone antagonism.
Chapagain A; Ashman N
QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
